Rilpivirine: 7 agencies, 2012–2025
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
The file has been open for more than a decade: 13.7 years separate the first record, 13 Feb 2012 at SMC (Scotland), from the most recent, 8 Oct 2025 at HAS (France).
CIPM (Spain) changed its position: not recommended on 2 Jun 2022, recommended by 24 Sep 2025, after a resubmission.
No assessment is on file from PBAC (Australia), which is among the eight highest-volume agencies here.
The file is active: 3 of 17 records date from 2023 or later.
3 distinct indication wordings are recorded for rilpivirine by the agencies that label one in English (AWMSG and SMC).
SMC (Scotland) was first to assess rilpivirine, on 13 Feb 2012; CIPM (Spain) did not open a file until 2 Jun 2022 — an unusually long tail of 10.3 years between the earliest and latest system to look at it.
The record arrives in waves: 5 separate years each carry two or more decisions, spread across 9 years in total.
5 of the 7 agencies here assessed rilpivirine more than once, HAS (France) most often at 5 entries — repeat review is the norm for this molecule rather than the exception.
7 of the 18 agencies in this archive hold a record for rilpivirine.
The full ledger for rilpivirine reads 10 recommended, 3 not recommended, 2 no benefit and 1 deferred to NICE, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CIPM (Spain) | 24 Sep 2025 | Indicación terapéutica autorizada: REKAMBYS está indicado, en combinación con cabotegravir inyectable, para el tratamien… | financed by the SNS · art. 92 a, c | source |
| HAS (France) | 1 Feb 2023 | Re-assessment of SMR and ASMR | SMR insufficient · ASMR V | source |
| G-BA (Germany) | 21 Oct 2021 | Rekambys — benefit assessment §35a | added benefit: not proven | source |
| AWMSG (Wales) | 22 Dec 2020 | In combination with cabotegravir injection, for the treatment of human immunodeficiency virus type 1 (HIV‑1) infection i… | excluded, NICE appraised | source |
| SMC (Scotland) | 8 Aug 2016 | In combination with other antiretroviral medicinal products, for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naïve … | accepted | source |
12 further decisions for rilpivirine, across 7 agencies, are not shown here. They include the most recent record on file, 8 Oct 2025 from HAS (France); its outcome is in the subscriber dataset. They link to 9 further source documents.
Related molecules
- raltegravir — divergent outcome (recommended vs restricted) on a shared indication
- sofosbuvir — same ATC class J05A — Antivirals
- letermovir — same ATC class J05A — Antivirals
- cabotegravir — same ATC class J05A — Antivirals
- tenofovir — same ATC class J05A — Antivirals
- darunavir — same ATC class J05A — Antivirals
Coverage: 17 decisions for rilpivirine from 7 agencies, 2012 to 2025. Data to 7 Sep 2026. ATC class J05A — Antivirals. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.